Restasis (cyclosporine ophthalmic emulsion) is a prescription drug that’s used to treat dry eye syndrome. The drug comes as an emulsion (oily liquid). You usually apply 1 drop into each affected eye ...

You may qualify for free Restasis through the drug’s manufacturer, myAbbVie Assist. That said, you won’t use your Medicare coverage. Restasis (cyclosporine), a brand-name eye drop for chronic dry eyes ...

Yes, people with Medicare Part D who use Restasis may be eligible for a patient assistance program called myAbbVie Assist. This article discusses whether Medicare covers Restasis, Medicare ...

Viatris VTRS announced that the FDA has approved the abbreviated new drug application filed by Mylan Pharmaceuticals, a subsidiary of Viatris, which sought approval for a generic version of Restasis ...

Why are Americans, both as patients and taxpayers, paying billions of dollars for a drug whose efficacy is so questionable that it's not approved in the European Union, Australia or New Zealand?

Restasis (cyclosporine) is prescribed for chronic dry eye. This drug has no known drug interactions. But when used with certain eye agents, studies found it’s not effective at improving dry eye ...

Allergan plc AGN recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S. It is the first and only prescription ...

(RTTNews) - Viatris Inc. (VTRS) said that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ...

DUBLIN, Jan. 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that its subsidiary, Watson Laboratories, Inc., has submitted an Abbreviated New Drug Application (ANDA) with the U.S.

Please provide your email address to receive an email when new articles are posted on . They said it would never happen. We would never see it in our lifetimes. It was a dream held by millions, but ...